CA-NOVAKID
26.7.2022 08:02:06 CEST | Business Wire | Press release
Novakid, Europe’s leading online English platform for children and an established EdTech company reinventing learning English as a Second Language (ESL), increased its presence in Asia-Pacific and conducted 2.8 M lessons during the first half of 2022.
During 1H2022, Novakid continued to strengthen its positions in 49 markets across the globe. As a result, the company's current client portfolio in Europe accounts for 70%, with Romania as a new growth market in Europe. The MENA region (Middle East and North Africa) accounts for 14% (2pp increase since the end of 2021). The Asia-Pacific countries (Malaysia, Indonesia, Japan and South Korea), now represent almost 16% of the company’s portfolio. The client base in the region has grown twice over compared to the beginning of the year. The most significant results are demonstrated in South Korea (34%) and Japan (78%).
“To operate successfully in the highly competitive international EdTech and ESL markets, businesses need strong diversification strategies, especially in these times of social and economic uncertainty. For this reason, Novakid’s priority for the first half of 2022 was to focus on new growth regions - Hong Kong, Japan and South Korea - where online language learning is driven by the massive digitalization of education over the last few years,” said Dmitry Malin , co-founder and COO of Novakid.
The total number of English lessons conducted on Novakid’s proprietary software since the beginning of 2022 reached 2.8 million, which is 15% higher than the total number of classes delivered during 2021 (2.4 million). At peak times, the platform hosted up to 1,400 lessons simultaneously.
Novakid has increased its teaching staff to nearly 2,700 native English speakers and near-native tutors. The company has continued to improve the qualifications of its teachers by launching a series of webinars and training courses.
The focus during H12022 was the further development of quality and innovative educational content for learning English. Following the release of the first-ever product on the ESL market - Novakid Magic Academy, a story-based, gamified English learning environment - at the end of 2021, Novakid has implemented this curriculum with over 130,000 students of all ages and levels in 6 months.
The Novakid Magic Academy, which forms part of the Novakid Game World, has proven its effectiveness with regards to the learning outcomes of young students: the average learning performance rate is 12% higher after a minimum of four months of lessons, resulting in a 39% better learning performance for students enrolled in the Level I Novakid Magic Academy ESL course. Speech-to-text solutions and emotion recognition software are being developed to make the in-lesson analysis more advanced.
For the second year in a row, Novakid has been included in the annual GSV EdTech top 150 list of the leading private companies in the digital learning space. In March 2022, Novakid was included on the Forbes Top 500 list of America’s Best Startup Employers . Novakid has also been recognised as a finalist in the 2022 EdTech Digest Awards in the category ‘Best Language Learning Solution’.
In June 2022, Novakid was selected as the winner of the “Overall Language Learning Company of the Year” in the 2022 EdTech Breakthrough Awards . Analysts studied the work of more than 80 online schools operating in Europe. The experts assessed the number of active students and their level of satisfaction with the educational process, the level of training and experience of teachers, as well as prices.
“The combination of product expansion and innovation over the past six months has led to impressive growth. We rolled out our new gamified story-based English curriculum - Novakid Game World - to all students during H12022, and can proudly guarantee that the methodology, which is based on engagement, leads students to language proficiency. The results of our young English learners are the biggest achievement for Novakid,” commented Max Azarov , co-founder and CEO of Novakid.
Accelerated by Covid-19, the online ESL industry for both children and adult students is set to continue its growth trajectory for the next few decades. According to the latest research study Online Language Learning Market run by Facts & Factors, the market is predicted to grow to around $28,5 billion by 2028 with a CAGR of around 18,8% during the period 2022 to 2028. At the same time, the K-12 education market is growing at a compound annual growth rate of 31,6% over the next 5 years according to Mordor Intelligence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005516/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
